MGUS at a glance- click the illustration below:
The challenge with a diagnosis of pre-MM is that it can lead to a diagnosis of multiple myeloma, an incurable blood cancer. And according to the article below, “Monoclonal Gammopathy of Undetermined Significance cohorts have a comparatively lower life expectancy…”
As the article linked and excerpted below states, “““The risk of progression is approximately 1% per year,…”The important point to keep in mind is that this 1% per year persists indefinitely, I believe.””
The question is, can the pre-MM patient reduce or eliminate his/her risk progressing to MM? Yes, according to the short video linked below. According to the study talked about in the video, curcumin and diet can slow the progression of pre-MM to MM. In addition there are evidence-based therapies that act like curcumin does as an anti-oxidant, anti-inflammatory, etc. supplement.
I am both a long-term MM survivor and MM cancer coach. I have lived in complete remission from my multiple myeloma since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
If you do not want to “watch and wait” to see if your Monoclonal Gammopathy of Undetermined Significance progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
Consider evidence-based, non-toxic therapies such as:
Turmeric Curcumin, MGUS, and Multiple Myeloma
Pre-MM may progress to multiple myeloma, AL amyloidosis, Waldenstrom’s macroglobulinemia, or lymphoma. But not all cases progress to malignancy.
“Much, however, remains a mystery, including the curious fact…that Monoclonal Gammopathy of Undetermined Significance cohorts have a comparatively lower life expectancy, “which is not entirely explained by the risk of malignant transformation.”1
“The median interval from recognition of the monoclonal protein to diagnosis of multiple myeloma was 64 months,” he (Dr. Robert Kyle) wrote in his landmark study, “of macroglobulinemia 103 months and of amyloidosis 92 months.”
“The risk of progression is approximately 1% per year,” Dr Kyle explained by phone. “The important point to keep in mind is that this 1% per year persists indefinitely, I believe.”
The risk factors for progression include the size of the serum M protein, the protein type, the number of plasma cells in the bone marrow, and the serum free light chain ratio…”
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”